Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
RESEARCH TOOLSreports
Holding IOVA?
Track your performance easily
IOVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.21 - $18.33
Previous Close$10.01
Volume6.73M
Average Volume (3M)7.11M
Market Cap
$3.17B
Enterprise Value$2.84B
Total Cash (Recent Filing)$412.54M
Total Debt (Recent Filing)$81.68M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Nov 06, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding303,513,872
10 Day Avg. Volume5,350,605
30 Day Avg. Volume7,109,697
Standard Deviation0.27
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.71
Price to Sales (P/S)96.87
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue86.78
Enterprise Value/Gross Profit-297.29
Enterprise Value/Ebitda-14.80
Forecast
1Y Price Target
$22.71Price Target Upside126.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Iovance Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ2 gross margin was 26% and should ramp pretty swiftly to ~70% in the next few years.
Product SalesA surprise $18.3MM of Proleukin sales was reported, more than offsetting the Q2 miss.
Revenue GuidanceManagement provided 2024 and 2025 sales guidance, which was bold and above expectations.
Bears Say
Clinical Trial OutcomesNeoadjuvant ipi-nivo did not increase surgery related grade 3+ adverse events; however, systemic related grade 3+ adverse events were doubled.
Manufacturing And InfrastructureStaffing constraints and infrastructural capacity limit the number of patients that can be treated monthly.
Product LaunchInitial metrics point to a slow launch, with just ~10-15% of 'enrolled' patients having been infused with commercial Amtagvi in the full first quarter since approval.
---
Ownership Overview
11.63% Insiders
16.60% Mutual Funds
53.52% Other Institutional Investors
18.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $3.21 and its highest was $18.33 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Currently, no data Available
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Nov 06, 2024 which is in 60 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Aug 08, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.353 by $0.013.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -$0.3.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 303,513,900 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.353. Following the earnings report the stock price went up 24.937%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Among the largest hedge funds holding Iovance Biotherapeutics Inc’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics Inc’s shares valued at 208M.
---
Iovance Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.71 (126.87% Upside)
$22.71 (126.87% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 96%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.11%
12-Months-Change
Fundamentals
Return on Equity
-65.36%
Trailing 12-Months
Asset Growth
27.34%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
---
IOVA Earnings Call
Q2 2024
0:00 / 0:00
---
IOVA Stock 12 Month Forecast
Average Price Target
$22.71
▲(126.87% Upside)
Technical Analysis
Best Analysts Covering IOVA
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+8.95%
reiterated a buy rating 30 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +8.95% per trade.
---